United Therapeutics Corporation (NASDAQ: UTHR) shares are trading lower by $8.00 at $127.34 in Monday's session.
Investors are exiting the issue following the announcement that the U.S. launch of RemoSynch will be delayed due to regulatory...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to United Therapeutics (UTHR):